Fudan-LSE Lecture Series No.28
TITLE:
Neuroscience, Ethics and Governance
神经科学伦理与治理
SPEAKER/主讲人:
HOST/主持人:
TIME/时间:
VENUE/地点:
Jonathan D. Moreno
Prof. Jing Yijia
18:30-20:30, Dec 9, 2019
Room 406, West Sub Building, Guanghua Towers
乔纳森·莫雷诺 教授
敬乂嘉 教授
2019年12月9日 18:30-20:30
光华楼西辅楼406室
THE SPEAKER
David and Lyn Silfen University Professor of University of Pennsylvania, Department of Medical Ethics and Health Policy, Department of History and Sociology of Science.He is an elected member of the National Academy of Medicine where he chairs the Interest Group on Human Rights, Professionalism and the Values of Medicine, and is the U.S. member of the UNESCO International Bioethics Committee.
ABSTRACT
This presentation will summarize the emergence of modern neuroscience, gives examples of the ways the neuroscience is leading to new neurotechnology-based drugs and devices, and describes a number of 'governance gaps' in the current global standards for neuroscience research and applications. These gaps range from weapons development to brain technologies that raise questions about human nature.
Ethics, Genomics, and Precision Medicine
基因组学、精密医学伦理探讨
Steven Joffe, MD, MPH 史蒂文·乔夫 教授
Founders Professor and Interim Chair, Department of Medical Ethics and Health Policy University of Pennsylvania. Dr. Joffe’s research addresses the ethical challenges that arise in the conduct of clinical and translational science and in genomic medicine. He serves as a member of the FDA’s Pediatrics Ethics Subcommittee, the National Institutes of Health Clinical Center Board of Scientific Counselors, and the National Human Genome Research Institute’s Genomics and Society Working Group.
Precision medicine seeks to use patients’ characteristics, especially genetics, to individualize treatment in ways that maximize benefits and minimize risks.
We are beginning to see the benefits of precision medicine, including in the treatment of cancer and some genetic diseases. However, precision medicine also presents a number of ethical challenges. These include the quality of the evidence behind individualized treatments, the effectiveness of precision medicine approaches, the high costs of precision medicine treatments, and the likelihood of inequity in its application both within and between countries.
ORGANIZERS
Institute for Global Public Policy (IGPP)
LSE-Fudan Research Centre for Global Public Policy
Center for Biomedical Ethics, Fudan University
